IMPDH2 Antibody
Description
IMPDH2 Overview
IMPDH2 catalyzes the conversion of inosine 5'-monophosphate (IMP) to xanthosine 5'-monophosphate (XMP), the rate-limiting step in de novo guanine nucleotide synthesis . This enzyme is upregulated in proliferating cells and malignancies, making it a biomarker for cancer aggressiveness and a therapeutic target . IMPDH2’s nuclear localization has recently been linked to PARP1-mediated DNA repair via NAD+ modulation .
IMPDH2 Antibody Applications
IMPDH2 antibodies are widely used in:
-
Western blotting (WB): Detects endogenous IMPDH2 at ~55–56 kDa .
-
Immunoprecipitation (IP): Identifies protein interactions, such as IMPDH2’s association with anti-apoptotic pathways .
-
Immunohistochemistry (IHC): Highlights IMPDH2 overexpression in hepatocellular carcinoma (HCC) and nasopharyngeal carcinoma (NPC) .
-
Immunofluorescence (IF): Visualizes IMPDH2 clustering into cytoophidia (rod/ring structures) under nucleotide stress .
IMPDH2 in Chemotherapy Resistance
-
Triple-negative breast cancer (TNBC): IMPDH2 overexpression correlates with doxorubicin resistance and poor recurrence-free survival. Pharmacological inhibition (e.g., mycophenolic acid) reduces tumor growth in vitro and in vivo .
-
Mechanistic insights: IMPDH2 knockdown decreases intracellular GTP levels by 20–50%, impairing survival pathways in resistant cells . Catalytically inactive IMPDH2 mutants fail to restore chemoresistance, confirming its enzymatic dependency .
Non-Canonical Roles in DNA Repair
-
PARP1 interaction: Nuclear IMPDH2 modulates NAD+ availability, enhancing PARP1 activity during DNA damage response. TNBC tissues show elevated nuclear IMPDH2, linking it to genomic instability .
Technical Validation
-
Specificity: Antibodies like MAB8349 show no cross-reactivity with IMPDH1 despite 84% amino acid similarity .
-
Functional assays: Microinjection of anti-IMPDH2 antibodies disassembles cytoophidia in COS-7 cells, confirming target engagement .
-
Clinical relevance: IHC-validated IMPDH2 antibodies correlate staining intensity with tumor grade and patient outcomes .
Product Specs
Target Background
- Our research indicates that IMPDH2 can serve as an independent prognostic biomarker for nasopharyngeal carcinoma (NPC) patients. High IMPDH expression suggests a poorer prognosis in these patients. PMID: 28389646
- IMPDH2, inosine-5'-monophosphate dehydrogenase 2, is an intracellular target of the PPIA-Sanglifehrin A binary complex. PMID: 28076787
- Rod and ring formation might be an adaptive homeostatic mechanism, enabling IMPDH to sense changes in the one-carbon folate pathway. PMID: 27343244
- Our findings indicate that the natural product myricetin exhibits potent anti-leukemia activity by interfering with the purine nucleotides biosynthetic pathway through the suppression of hIMPDH1/2 catalytic activity. PMID: 27378425
- Our findings suggest that overexpressed IMPDH2 can be utilized as a biomarker for the diagnosis of kidney and bladder cancer and represents a potential therapeutic target for these diseases. PMID: 25465060
- IMPDH2 is directly involved in the development of chemoresistance and radioresistance in osteosarcoma cells. PMID: 25392102
- Compared to non-cancerous prostate tissues, both IMPDH2 mRNA and protein expression levels were significantly upregulated in prostate cancer tissues. PMID: 24659377
- Our findings highlight the localization of IMPDH2 within the nucleus of human cells, along with the ultrastructure of R&R inclusions. PMID: 24980853
- Rods and rings (RR) are protein assemblies composed of CTPS1 and IMPDH2. Glutamine deprivation initiates the reversible assembly of mammalian rods and rings. PMID: 24477477
- This study provides insights into the dynamics of conserved water-mediated salt bridge interactions and interdomain recognition in hIMPDH isoforms. PMID: 22928911
- This research provides insights into the role of salt bridge dynamics in interdomain recognition of human IMPDH isoforms, offering information about inhibitor topology for isoform-II. PMID: 22066532
- This ethnically-specific data may contribute to a better understanding of the variability in clinical outcomes and/or dose adjustments of drugs that are IMPDH inhibitors, such as mycophenolic acid. PMID: 21181270
- The 3757C allele was associated with higher lymphocyte counts and a reduced incidence of lymphopenia among kidney allograft recipients. PMID: 21996196
- Anti-IMPDH2 antibodies might lead to difficulties in interpreting immunofluorescence patterns during routine autoantibody testing. PMID: 22029192
- IMPDHII plays a crucial role in the negative regulation of TLR2 signaling by modulating PI3K activity. PMID: 21460227
- In the absence of a ligand, the mobilities of the "flap" and "loop" regions of IMPDH-II (1B3O) structures are primarily controlled by the four (W 1, W 2, W 3, and W 4) conserved water molecular centers and their dynamics. PMID: 20135634
- We resequenced IMPDH1 and IMPDH2 using DNA from 288 individuals across three ethnic groups and conducted functional genomic studies of the identified sequence variants. This identified 25 SNPs, 24 of which were novel, in IMPDH2. PMID: 20718729
- IMPDH2 is directly involved in the development of chemoresistance in osteosarcoma cells. PMID: 20808934
- We investigated IMPDH2 genetic polymorphism in 96 individuals of Caucasian origin. PMID: 19810816
- Pharmacogenetic analysis of IMPDH II could represent a novel approach for therapeutic monitoring of mycophenolate mofetil. PMID: 15621150
- We identified nine genetic variants in the IMPDH2 gene, with frequencies of the rarer alleles ranging from 0.5 to 10.2%. PMID: 17496727
- IMPDH2 serves as a marker gene useful for stratifying osteosarcoma patients into low- and high-risk groups, predicting therapy outcomes. PMID: 17660802
- We investigated the effect of diabetes mellitus on mycophenolic acid pharmacokinetics and the catalytic activity of inosine monophosphate dehydrogenase 2 in maintenance kidney transplant recipients. PMID: 18043470
- This study reports the synthesis and activity of several novel inhibitors of IMPDH2. PMID: 18583139
- In vivo analysis of C-MYC interactions with TS, IMPDH2, and PRPS2 genes confirmed that they are direct C-MYC targets. PMID: 18677108
- The expression of IMPDH2 in tumor tissue was significantly higher in patients with colorectal cancer compared to healthy subjects. PMID: 19597826
- The IMPDH type II 3757T > C polymorphism is associated with increased IMPDH activity in MMF-treated renal transplant patients. PMID: 19617864
